Cannmedic

Cannmedic is an Israeli medical cannabis company specializing in the research, cultivation, and production of pharmaceutical-grade cannabis strains. As one of the pioneering licensed producers in Israel, the company has developed a portfolio of proprietary genetics tailored for specific medical indications, most notably the high-CBD strain EP-1 used for refractory epilepsy. Cannmedic's operations adhere to rigorous GACP and GMP standards, ensuring the delivery of consistent therapeutic oils and inflorescences to patients. The company is a subsidiary of Better Cannabis (Better Holdings) and has been a key participant in clinical research exploring the efficacy of cannabinoids in treating autism and neurological disorders. Their products are distributed both within the Israeli domestic market and through international export partnerships.